MET and neoplasm: As a result, a WZB117-MET combination, in where WZB117 reduces glucose levels at the tumor site by inhibiting GLUT1 receptors and synergistically enhances MET therapeutic efficacy to induce apoptosis, might be a promising approach to target cancer cell metabolism.